Injection Site Pain Comparison of Excipient Solutions

PHASE1CompletedINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

July 20, 2020

Primary Completion Date

September 24, 2020

Study Completion Date

September 25, 2020

Conditions
Obesity
Interventions
OTHER

Trial product 1

Buffering agent: N/A Isotonic agent: NaCl 9.0 mg/mL

OTHER

Trial product 2

Buffering agent: Disodium hydrogen phosphate, dihydrate 1.42 mg/mL Isotonic agent: NaCl 8.25 mg/mL

OTHER

Trial product 3

Buffering agent: Disodium hydrogen phosphate dihydrate 1.42 mg/mL Isotonic agent: Propylene glycol 18.5 mg/mL

OTHER

Trial product 4

Buffering agent: Disodium hydrogen phosphate dihydrate 1.42 mg/mL Isotonic agent: Glycerol 22.0 mg/mL

OTHER

Trial product 5

Buffering agent: Disodium hydrogen phosphate dihydrate 1.42 mg/mL Isotonic agent: Mannitol 44.0 mg/mL

OTHER

Trial product 6

Buffering agent: Disodium hydrogen phosphate dihydrate 1.42 mg/mL Isotonic agent: Sucrose 82.0 mg/mL

OTHER

Trial product 7

Buffering agent: Disodium hydrogen phosphate dihydrate 1.42 mg/mL Isotonic agent: a,a-Trehalose, dihydrate 90.0 mg/mL

OTHER

Trial product 8

Buffering agent: Disodium hydrogen phosphate dihydrate 5.34 mg/mL Isotonic agent: NaCl 6.72 mg/mL

OTHER

Trial product 9

Buffering agent: Tris 2.4 mg/mL Isotonic agent: Propylene glycol 19 mg/mL

OTHER

Trial product 10

Buffering agent: Glutamic acid 0.74 mg/mL Isotonic agent: Glycerol 24.0 mg/mL

OTHER

Trial product 10

Buffering agent: Sodium Acetate, trihydrate 0.68 mg/mL Isotonic agent: Glycerol 24.0 mg/mL

OTHER

Trial product 12

Buffering agent: Glutamic acid 0.46 mg/mL, Disodium hydrogen phosphate, dihydrate 2.00 mg/mL Isotonic agent: Glycerol 15 mg/mL, NaCl 2.5 mg/mL

Trial Locations (1)

9728 NZ

Novo Nordisk Investigational Site, Groningen

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY